The Paclitaxel-eluting PTCA-balloon in combination with a cobalt-chromium stent in two different sequences to treat de novo coronary artery lesions: An angiographic follow up study
| Autor: | Praveen Chandra, Upendra Kaul, Michael Boxberger, Paramdeep Singh Sandhu, Ajit S. Mullesari, Ashok Seth, Oommen K George, Vinay K. Bahl, Shirish Hiremath, Martin Unverdorben, Ralf Degenhardt, Seshagiri Rao, Hanns Ackermann |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Chromium
Male medicine.medical_specialty Drug coated balloon RD1-811 Paclitaxel medicine.medical_treatment India Balloon Coronary Angiography Risk Assessment Severity of Illness Index Coronary Restenosis chemistry.chemical_compound Restenosis Bail out stenting medicine Diseases of the circulatory (Cardiovascular) system Humans Prospective Studies Angioplasty Balloon Coronary Prospective cohort study Survival rate Aged business.industry Incidence Balloon catheter Coronary Stenosis Stent Drug-Eluting Stents Cobalt Middle Aged medicine.disease Surgery Survival Rate medicine.anatomical_structure Treatment Outcome chemistry RC666-701 Original Article Female Radiology business Cardiology and Cardiovascular Medicine Artery Follow-Up Studies |
| Zdroj: | Indian Heart Journal, Vol 65, Iss 5, Pp 510-517 (2013) |
| Popis: | Introduction: The paclitaxel-coated balloon catheter (DCB) based on the PACCOCATH® technology has yielded angiographic and clinical results superior to drug-eluting stents (DES) in situations like in-stent restenosis (ISR) and a trend towards superior results in small coronary vessels and side branches of coronary bifurcations. Using the DCB followed by cobalt–chromium stent (CoCr) deployment or with a reverse sequence may yield different outcomes in terms of late loss. Methods: 97 patients with de-novo coronary stenosis (55.6 ± 10.7 years, 79.4% male, ≥70%, length: ≤25 mm, vessel diameter: 2.5–4.0 mm) were randomly treated with the DCB (3 μg/mm²) followed by a CoCr-stent or stent first and DCB later. Six-month angiographic and one-year clinical follow-up intention-to-treat analyses were performed. Results: Angiographic and demographic baseline data was comparable between the two groups. When comparing balloon first versus stent first technique, the primary outcome variables were not statistically different for mean in-segment (0.51 ± 0.56 mm vs. 0.36 ± 0.55 mm, p = 0.23) and in-stent (0.52 ± 0.55 mm vs. 0.46 ± 0.52 mm, p = 0.65) late lumen loss. The lesion related 12-month MACE rates were 5/49 (10.2%) and 2/48 (4.2%) (p = 0.44). Lesion related thrombotic events occurred in three patients in balloon first and in one patient in stent first group, two of which were associated with early discontinuation of continuous dual anti-platelet therapy, two with suboptimal PCI, and one each were performed in a thrombotic lesion and a bifurcation type 1.1.0. Conclusion: Drug-coated balloon first followed by cobalt chromium stent deployment versus a reverse sequence is not associated with statistically significantly different 6-month angiographic or 12-month clinical outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|